Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was ...

    Research Article last updated 12/09/2015 - 8:56am.

  2. Foundation Update - July 2016

    ... to play with my friends. I have to go the hospital to get transfusion blood. Everyone at the hospital says people are working hard to find medicines, ...

    Article last updated 10/09/2017 - 2:53pm.

  3. Brittany Springer – Aplastic Anemia Patient “Just Focused on Beating It”

    ... due to my work and school schedule. She ran a regular CBC blood test.  The next day,  I was surprised to see I had missed a call ... she thought I might have leukemia. She told me I needed a transfusion (my platelet count was 56). I was so upset I could not ...

    Patient Chronicle last updated 04/29/2016 - 3:29pm.

  4. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by CH50 ≤10% of ...

    Research Article last updated 01/20/2015 - 2:28pm.

  5. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and ... achieved long-term packed red blood cell PRBC transfusion independence , and all PRCA responders achieved long-term ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk ... of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) independently ...

    Research Article last updated 07/28/2014 - 8:53am.

  8. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6months in the ESA and ... and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should ...

    Research Article last updated 07/28/2014 - 9:30am.

  9. Front-line immunosuppressive treatment of acquired aplastic anemia

    ... 60 and 80%. CsA should be given for 12 months until transfusion independence is achieved and then tapered very slowly in the ... are usually continued on CsA. Tight monitoring of the blood count during CsA tapering is necessary to identify early loss of ...

    Research Article last updated 01/02/2013 - 2:48pm.

  10. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... of hematopoiesis that results in peripheral blood cytopenias and a marked propensity to progress to acute myelogenous ... Although supportive or palliative measures such as blood transfusion have long been the mainstay of management of MDS, ...

    Research Article last updated 10/11/2011 - 5:58pm.